OBJECTIVE: Galectin-3, reflecting cardiac fibrosis, is a promising biomarker in early detection of heart failure with preserved ejection fraction (HFpEF). We aimed to clarify the clinical utility of galectin-3 levels in the diagnosis of HFpEF and to compare galectin-3 with N-terminal pro-brain-type natriuretic peptide (NT-proBNP) levels. METHODS AND RESULTS: The study included 44 HFpEF patients (mean age 60 ± 6.78 years, 24 men) and 38 control subjects (mean age 57 ± 8.98 years, 20 men). Galectin-3 and NT-proBNP levels were assessed by the ELISA kits. The receiver operating characteristics (ROC) curve was used to examine the diagnostic performance of galectin-3 and NT-proBNP in HFpEF. Galectin-3 and NT-proBNP levels were significantly increased in patients with HFpEF compared to controls [5.35 ng/ml (0.86 – 14.90) vs 0.51 ng/ml (0.15 – 1.71) P < 0.0001, 617.75 ± 271.30 pg/ml vs 66.35 ± 54.01 pg/ml P < 0.0001, respectively]. Galectin-3 correlated with NT-proBNP, left atrial volume index, left ventricular mass index, and E/E’ (r = 0.90, P < 0.0001; r = 0.75, P = 0.0001; r = 0.86, P = 0.0001; r = 0.80, P = 0.0001; respectively). The area under the ROC curve was 0.98 for galectin-3 and 1.0 for NT-proBNP. CONCLUSIONS: Our results support that, in addition to NT-proBNP, galectin-3 is also a valuable biomarker for the diagnosis of patients with HFpEF.
OBJECTIVE:Galectin-3, reflecting cardiac fibrosis, is a promising biomarker in early detection of heart failure with preserved ejection fraction (HFpEF). We aimed to clarify the clinical utility of galectin-3 levels in the diagnosis of HFpEF and to compare galectin-3 with N-terminal pro-brain-type natriuretic peptide (NT-proBNP) levels. METHODS AND RESULTS: The study included 44 HFpEF patients (mean age 60 ± 6.78 years, 24 men) and 38 control subjects (mean age 57 ± 8.98 years, 20 men). Galectin-3 and NT-proBNP levels were assessed by the ELISA kits. The receiver operating characteristics (ROC) curve was used to examine the diagnostic performance of galectin-3 and NT-proBNP in HFpEF. Galectin-3 and NT-proBNP levels were significantly increased in patients with HFpEF compared to controls [5.35 ng/ml (0.86 – 14.90) vs 0.51 ng/ml (0.15 – 1.71) P < 0.0001, 617.75 ± 271.30 pg/ml vs 66.35 ± 54.01 pg/ml P < 0.0001, respectively]. Galectin-3 correlated with NT-proBNP, left atrial volume index, left ventricular mass index, and E/E’ (r = 0.90, P < 0.0001; r = 0.75, P = 0.0001; r = 0.86, P = 0.0001; r = 0.80, P = 0.0001; respectively). The area under the ROC curve was 0.98 for galectin-3 and 1.0 for NT-proBNP. CONCLUSIONS: Our results support that, in addition to NT-proBNP, galectin-3 is also a valuable biomarker for the diagnosis of patients with HFpEF.
Authors: Michela Chianca; Giorgia Panichella; Iacopo Fabiani; Alberto Giannoni; Serena L'Abbate; Alberto Aimo; Annamaria Del Franco; Giuseppe Vergaro; Chrysanthos Grigoratos; Vincenzo Castiglione; Carlo Maria Cipolla; Antonella Fedele; Claudio Passino; Michele Emdin; Daniela Maria Cardinale Journal: Front Cardiovasc Med Date: 2022-07-06
Authors: Seung-Hyun Kim; Michael Behnes; Michele Natale; Julia Hoffmann; Nadine Reckord; Ursula Hoffmann; Johannes Budjan; Thomas Henzler; Theano Papavassiliu; Martin Borggrefe; Thomas Bertsch; Ibrahim Akin Journal: Dis Markers Date: 2016-12-01 Impact factor: 3.434
Authors: Tamara Pecherina; Anton Kutikhin; Vasily Kashtalap; Victoria Karetnikova; Olga Gruzdeva; Oksana Hryachkova; Olga Barbarash Journal: Diagnostics (Basel) Date: 2020-05-14
Authors: Manuel C Martos-Maldonado; Indalecio Quesada-Soriano; Luis García-Fuentes; Antonio Vargas-Berenguel Journal: Nanomaterials (Basel) Date: 2020-01-24 Impact factor: 5.076
Authors: Michiel T H M Henkens; Sharon Remmelzwaal; Emma L Robinson; Adriana J van Ballegooijen; Arantxa Barandiarán Aizpurua; Job A J Verdonschot; Anne G Raafs; Jerremy Weerts; Mark R Hazebroek; Sandra Sanders-van Wijk; M Louis Handoko; Hester M den Ruijter; Carolyn S P Lam; Rudolf A de Boer; Walter J Paulus; Vanessa P M van Empel; Rein Vos; Hans-Peter Brunner-La Rocca; Joline W J Beulens; Stephane R B Heymans Journal: Eur J Heart Fail Date: 2020-08-07 Impact factor: 15.534